{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:47:09Z","timestamp":1783432029073,"version":"3.54.6"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Patients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic anticoagulation with low molecular weight heparin or direct oral anticoagulants, although thrombocytopenia (platelet count less than 50,000\/\u03bcL) and other coagulopathies are relative contraindications. Patients with brain metastasis from melanoma, renal cell carcinoma, choriocarcinoma, thyroid carcinoma, and hepatocellular carcinoma have a higher tendency to bleed spontaneously than noted in patients with other malignancies, and thus warrant routine brain imaging and alternative strategies such as inferior vena cava filter placement in the acute setting of venous thromboembolism before consideration of therapeutic anticoagulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Malignant gliomas are associated with increased risks of both venous thromboses and intracranial hemorrhage, but the additional bleeding risk associated with therapeutic anticoagulation appears acceptable, especially after treatment of primary tumors. Most patients with treated brain metastasis have a low risk of intracranial hemorrhage associated with therapeutic anticoagulation, and low molecular weight heparin is currently the preferred agent of choice. Patients with untreated brain metastasis from melanoma, renal cell carcinoma, thyroid cancer, choriocarcinoma, and hepatocellular carcinoma have a higher propensity for spontaneous intracranial bleeding, and systemic anticoagulation may be contraindicated in the acute setting of venous thromboembolism.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0274","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T14:55:29Z","timestamp":1511189729000},"page":"468-473","source":"Crossref","is-referenced-by-count":37,"title":["Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis"],"prefix":"10.1093","volume":"23","author":[{"given":"Richard J.","family":"Lin","sequence":"first","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Green","sequence":"additional","affiliation":[{"name":"Laura and Isaac Perlmutter Cancer Center, New York University, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"2021122510435200500_onco12329-bib-0001","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/asheducation-2016.1.196","article-title":"Thrombosis in the setting of cancer","volume":"2016","author":"Streiff","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122510435200500_onco12329-bib-0002","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2021122510435200500_onco12329-bib-0003","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.1996.14.2.652","article-title":"Inferior vena cava filters in cancer patients: Indications and outcome","volume":"14","author":"Schwarz","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122510435200500_onco12329-bib-0004","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2005.04.6656","article-title":"Management of venous thromboembolism in patients with primary and metastatic brain tumors","volume":"24","author":"Gerber","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122510435200500_onco12329-bib-0005","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2021122510435200500_onco12329-bib-0006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11883-012-0250-3","article-title":"Intracranial hemorrhage in patients with cancer","volume":"14","author":"Velander","year":"2012","journal-title":"Curr Atheroscler Rep"},{"key":"2021122510435200500_onco12329-bib-0007","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/WNL.0b013e3181cef837","article-title":"Intracerebral and subarachnoid hemorrhage in patients with cancer","volume":"74","author":"Navi","year":"2010","journal-title":"Neurology"},{"key":"2021122510435200500_onco12329-bib-0008","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1055\/s-0033-1357483","article-title":"Brain neoplasms and coagulation","volume":"39","author":"Magnus","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"2021122510435200500_onco12329-bib-0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-005-6876-z","article-title":"Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage","volume":"76","author":"Jung","year":"2006","journal-title":"J Neurooncol"},{"key":"2021122510435200500_onco12329-bib-0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systemic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2021122510435200500_onco12329-bib-0011","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdn755","article-title":"Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia","volume":"20","author":"Chen","year":"2009","journal-title":"Ann Oncol"},{"key":"2021122510435200500_onco12329-bib-0012","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1741-7015-10-97","article-title":"Intracranial hemorrhage in adult patients with hematological malignancies","volume":"10","author":"Chen","year":"2012","journal-title":"BMC Med"},{"key":"2021122510435200500_onco12329-bib-0013","doi-asserted-by":"crossref","first-page":"e004199","DOI":"10.1136\/bmjopen-2013-004199","article-title":"Intracranial haemorrhage in thrombocytopenic haematology patients\u2014A nested case-control study: The InCiTe study protocol","volume":"4","author":"Estcourt","year":"2014","journal-title":"BMJ Open"},{"key":"2021122510435200500_onco12329-bib-0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro Oncol"},{"key":"2021122510435200500_onco12329-bib-0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence based review","volume":"89","author":"Marras","year":"2000","journal-title":"Cancer"},{"key":"2021122510435200500_onco12329-bib-0016","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0034-1370791","article-title":"Thrombosis in brain tumors","volume":"40","author":"Jo","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"2021122510435200500_onco12329-bib-0017","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cncr.20150","article-title":"ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas","volume":"100","author":"Streiff","year":"2004","journal-title":"Cancer"},{"key":"2021122510435200500_onco12329-bib-0018","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-015-1840-z","article-title":"A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: Hazard rate and risk factors","volume":"124","author":"Streiff","year":"2015","journal-title":"J Neurooncol"},{"key":"2021122510435200500_onco12329-bib-0019","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2016-06-720714","article-title":"Podoplanin expression in primary brain tumors induced platelet aggregation and increases risk of venous thromboembolism","volume":"129","author":"Riedl","year":"2017","journal-title":"Blood"},{"key":"2021122510435200500_onco12329-bib-0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ana.410130320","article-title":"Incidence and treatment of peripheral venous thrombosis in patients with glioma","volume":"13","author":"Ruff","year":"1983","journal-title":"Ann Neurol"},{"key":"2021122510435200500_onco12329-bib-0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3171\/jns.1987.66.3.0357","article-title":"Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism","volume":"66","author":"Choucair","year":"1987","journal-title":"J Neurosurg"},{"key":"2021122510435200500_onco12329-bib-0022","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1227\/00006123-199007000-00010","article-title":"The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors","volume":"27","author":"Altschuler","year":"1990","journal-title":"Neurosurgery"},{"key":"2021122510435200500_onco12329-bib-0023","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00006123-199910000-00022","article-title":"Anticoagulation in neurosurgical patients","volume":"45","author":"Lazio","year":"1999","journal-title":"Neurosurgery"},{"key":"2021122510435200500_onco12329-bib-0024","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1538-7836.2009.03690.x","article-title":"Venous thromboembolism in malignant gliomas","volume":"8","author":"Jenkins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2021122510435200500_onco12329-bib-0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11060-015-1805-2","article-title":"Venous thromboembolism (VTE) and glioblastoma","volume":"124","author":"Yust-Katz","year":"2015","journal-title":"J Neurooncol"},{"key":"2021122510435200500_onco12329-bib-0026","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood-2017-02-767285","article-title":"Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin","volume":"129","author":"Mantia","year":"2017","journal-title":"Blood"},{"key":"2021122510435200500_onco12329-bib-0027","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00415-002-0855-5","article-title":"Low molecular weight heparin for deep vein thrombosis in glioma patients","volume":"249","author":"Schmidt","year":"2002","journal-title":"J Neurol"},{"key":"2021122510435200500_onco12329-bib-0028","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122510435200500_onco12329-bib-0029","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/jth.12338","article-title":"Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH","volume":"11","author":"Carrier","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2021122510435200500_onco12329-bib-0030","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1212\/WNL.27.7.650","article-title":"Intracranial hemorrhage caused by metastatic tumors","volume":"27","author":"Mandybur","year":"1977","journal-title":"Neurology"},{"key":"2021122510435200500_onco12329-bib-0031","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1227\/00006123-198204000-00004","article-title":"Spontaneous intracranial hemorrhage caused by brain tumor: Its incidence and clinical significance","volume":"10","author":"Wakai","year":"1982","journal-title":"Neurosurgery"},{"key":"2021122510435200500_onco12329-bib-0032","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jocn.2008.05.010","article-title":"Prediction, clinical characteristics and prognosis of intracerebral hemorrhage in hepatocellular carcinoma patients with intracerebral metastasis","volume":"16","author":"Hsieh","year":"2009","journal-title":"J Clin Neurosci"},{"key":"2021122510435200500_onco12329-bib-0033","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/JTO.0b013e318194fad4","article-title":"Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients","volume":"4","author":"Srivastava","year":"2009","journal-title":"J Thorac Oncol"},{"key":"2021122510435200500_onco12329-bib-0034","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122510435200500_onco12329-bib-0035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.43.6.1111","article-title":"Complications of therapy for venous thromboembolic disease in patients with brain tumors","volume":"43","author":"Levin","year":"1993","journal-title":"Neurology"},{"key":"2021122510435200500_onco12329-bib-0036","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/1097-0142(19940115)73:2<493::AID-CNCR2820730240>3.0.CO;2-D","article-title":"Therapy of venous thromboembolism in patients with brain metastases","volume":"73","author":"Schiff","year":"1994","journal-title":"Cancer"},{"key":"2021122510435200500_onco12329-bib-0037","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1538-7836.2004.00853.x","article-title":"Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: A prospective cohort study","volume":"2","author":"Monreal","year":"2004","journal-title":"J Thromb Haemost"},{"key":"2021122510435200500_onco12329-bib-0038","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: A matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"key":"2021122510435200500_onco12329-bib-0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01052888","article-title":"Treatment of thromboembolic complications in patients with brain tumors","volume":"22","author":"Norris","year":"1994","journal-title":"J Neurooncol"},{"key":"2021122510435200500_onco12329-bib-0040","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/CMR.0b013e328353efd8","article-title":"Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases","volume":"22","author":"Alvarado","year":"2012","journal-title":"Melanoma Res"},{"key":"2021122510435200500_onco12329-bib-0041","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1001\/archinte.1987.00370120113020","article-title":"Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter?","volume":"147","author":"Olin","year":"1987","journal-title":"Arch Intern Med"},{"key":"2021122510435200500_onco12329-bib-0042","first-page":"391","article-title":"Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: A meta-analysis of randomised controlled trials","volume":"13","author":"Minno","year":"2015","journal-title":"Blood Transfus"},{"key":"2021122510435200500_onco12329-bib-0043","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2021122510435200500_onco12329-bib-0044","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11239-016-1429-1","article-title":"Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: A prospective cohort study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Throm Thrombolysis"},{"key":"2021122510435200500_onco12329-bib-0045","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: Results from the AMPLIFY trial","volume":"13","author":"Agnelli","year":"2015","journal-title":"J Thrombo Haemost"},{"key":"2021122510435200500_onco12329-bib-0046","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"key":"2021122510435200500_onco12329-bib-0047","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11239-016-1434-4","article-title":"Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"43","author":"Rojas-Hernandez","year":"2017","journal-title":"J Thromb Thrombolysis"},{"key":"2021122510435200500_onco12329-bib-0048","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1200\/JCO.2007.14.1283","article-title":"American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer","volume":"25","author":"Lyman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122510435200500_onco12329-bib-0049","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0049-3848(16)30100-1","article-title":"Intracranial hemorrhage in cancer patients treated with anticoagulation","volume":"140","author":"Weinstock","year":"2016","journal-title":"Thromb Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0274","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0274","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/468\/41915171\/oncolo_23_4_468.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/4\/468\/41915171\/oncolo_23_4_468.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:45:08Z","timestamp":1640429108000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/4\/468\/6439547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,11,20]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0274","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2017,11,20]]}}}